Last update: May 11, 2019


High Risk for breastfeeding

Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.

A centrally-acting antihypertensive and antiadrenergic agent structurally related to clonidine.
Indicated in the treatment of hypertension.
Oral administration once a day.

Its pharmacokinetic data - low plasma protein binding and low molecular weight (Kirsten 1998) - may possibly explain the excretion in breastmilk observed, whose amount could affect the infant (Schaefer 2007 p685, Schaefer 1998).

Moxonidine does not cause alterations in the secretion of prolactin (Bamberger 1995).

Until there is more published data on this drug in relation to breastfeeding (Schaefer 2007 p685), safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Μοξονιδίνη is Moxonidine in Greek.

Is written in other languages:


Μοξονιδίνη belongs to this group or family:


Main tradenames from several countries containing Μοξονιδίνη in its composition:


Variable Value Unit
Oral Bioavail. 88 %
Molecular weight 242 daltons
Protein Binding 7 %
VD 1.8 ± 0.4 l/Kg
pKa 7,26 -
Tmax 0,5 - 3 hours
T1/2 2 - 3 hours
M/P ratio 1 - 2 -
Theoretical Dose 0,0004 mg/Kg/d
Relative Dose 12,1 %


  1. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, second edition. London. 2007
  2. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract
  3. Schaefer HG, Toublanc N, Weimann HJ. The pharmacokinetics of moxonidine. Rev Contemp Pharmacother 1998; 9: 481–90. 1998
  4. Bamberger CM, Mönig H, Mill G, Gödde E, Schulte HM. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Exp Clin Endocrinol Diabetes. 1995 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM